26.09.2021, 2239 Zeichen

Marinomed: Marinomed Biotech AG, an Austrian science-based biotech company with globally marketed therapeutics derived from innovative proprietary technology platforms, announced today that starting October 2021, Stephanie Kniep will be heading the company’s Investor Relations (IR) activities. With her vast IR experience and knowledge, she will contribute to Marinomed’s strategic communications and positioning on the international capital markets. Stephanie Kniep is a renowned IR Manager with more than 20 years of experience.
Marinomed Biotech: weekly performance: 0.86%

Valneva: Valneva, an Austrian/French specialty vaccine company, announced that it has commenced recruitment of adolescents in its pivotal Phase 3 Clinical Trial (VLA2001-301, “Cov-Compare”) for its inactivated COVID-19 vaccine candidate VLA2001 in the United Kingdom. Topline results from the pivotal Cov-Compare trial are expected early in the fourth quarter of 2021 and are intended to form the basis for potential regulatory approval in adults. The Company has also started to provide boosters to volunteers in its Phase 1/2 VLA2001-201 trial. This planned expansion of VLA2001 clinical trials will support future approval in further age groups, in addition to adults. Further, the company said it continues discussions with the European Commission regarding a potential VLA2001 supply contract. The Company is also actively pursuing opportunities to make VLA2001 available to other customers, subject to positive Cov-Compare data and regulatory approval. CEO Thomas Lingelbach commented, “Our teams at Valneva remain fully committed to carry out VLA2001’s development plan and bring our inactivated vaccine to all patient groups who could benefit. We continue to receive messages on a daily basis from people across the world who are waiting for an inactivated vaccine so we continue to believe that our differentiated vaccine candidate could contribute to the ongoing fight against the COVID-19 pandemic. We’re confident that many countries, and regulators, will want to have the opportunity to consider our inactivated COVID-19 vaccine.”  
Valneva: weekly performance: 17.53%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (23/09/2021)

Christian Drastil: Wiener Börse Plausch

Börsepeople im Podcast S12/08: Robert Abend

Bildnachweis

Aktien auf dem Radar:Amag, Palfinger, SBO, Addiko Bank, Flughafen Wien, Austriacard Holdings AG, EVN, EuroTeleSites AG, Pierer Mobility, Semperit, Bawag, Kostad, Wolford, Oberbank AG Stamm, Polytec Group, ams-Osram, Agrana, CA Immo, Erste Group, Immofinanz, Kapsch TrafficCom, Mayr-Melnhof, OMV, Österreichische Post, Strabag, Telekom Austria, Uniqa, VIG, Wienerberger, Covestro, Sartorius.

---